Administration Expression after Secondary Vector Expression in the Lung and Facilitates Adenovirus-Mediated Transgene Ligand Interactions Prolongs Transient Inhibition of CD 28 and CD 40

[1]  M. Kay,et al.  Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo , 1997, Nature Biotechnology.

[2]  J. Zabner,et al.  Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. , 1997, The Journal of clinical investigation.

[3]  P. Linsley,et al.  Do effector and memory T helper cells also need B7 ligand costimulatory signals? , 1997, Journal of immunology.

[4]  L. Meuse,et al.  Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression , 1997, Gene Therapy.

[5]  J. Mcghee,et al.  Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. , 1997, Journal of immunology.

[6]  A. Beaudet,et al.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. , 1997, Human gene therapy.

[7]  H. Zhou,et al.  Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo , 1997, Journal of virology.

[8]  W. Song,et al.  Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. , 1997, Human gene therapy.

[9]  R. Gregory,et al.  Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway , 1997, Gene Therapy.

[10]  M. Mehtali,et al.  Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression , 1997, Gene Therapy.

[11]  A. Gown,et al.  Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Droguett,et al.  Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E. Butcher,et al.  Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.

[14]  B. Davidson,et al.  Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[15]  S. Kochanek,et al.  Persistence in muscle of an adenoviral vector that lacks all viral genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Flavell,et al.  The Cd40 ligand , 1997, Immunologic research.

[17]  J. Wilson,et al.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.

[18]  J. Wilson,et al.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. , 1996, Human molecular genetics.

[19]  James M. Wilson,et al.  Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs , 1996, Journal of virology.

[20]  R. Flavell,et al.  Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues , 1996, Journal of virology.

[21]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[22]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[23]  J. Wilson,et al.  Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. , 1996, Gene therapy.

[24]  J. Leiden,et al.  Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.

[25]  Peter S. Linsley,et al.  The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells , 1996, The Journal of experimental medicine.

[26]  H. Ertl,et al.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.

[27]  M. Schuyler,et al.  The Regulation of Pulmonary Immunity , 1995, Advances in Immunology.

[28]  A. Pavirani,et al.  Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vector , 1995, European journal of immunology.

[29]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[30]  A. Gown,et al.  Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration , 1995, Nature Genetics.

[31]  M. Kay,et al.  Immunomodulation to enhance gene therapy , 1995, Nature Medicine.

[32]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[33]  J. Whitsett,et al.  Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. , 1995, Human gene therapy.

[34]  M. Kay,et al.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. , 1995, Gene therapy.

[35]  M. Kay,et al.  Therapeutic serum concentrations of human alpha‐1‐antitrypsin after adenoviral‐mediated gene transfer into mouse hepatocytes , 1995, Hepatology.

[36]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  James M. Wilson,et al.  Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans , 1994, Nature.

[38]  H. Ertl,et al.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.

[39]  James M. Wilson,et al.  Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis , 1994, Nature Genetics.

[40]  J. Wilson,et al.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Perricaudet,et al.  Widespread long-term gene transfer to mouse skeletal muscles and heart. , 1992, The Journal of clinical investigation.

[42]  R. Chanock,et al.  A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Farson,et al.  Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. , 1997, Gene therapy.

[44]  J Bajorath,et al.  Immune regulation by CD40 and its ligand GP39. , 1996, Annual review of immunology.

[45]  R. Noelle,et al.  Functions of CD40 and its ligand, gp39 (CD40L). , 1996, Critical reviews in immunology.

[46]  F. Graham,et al.  Adenovirus-based expression vectors and recombinant vaccines. , 1992, Biotechnology.